Clinical Trials & Research

23 November 2020  Two different dosing regimens demonstrated efficacy with one showing a better profile No hospitalisations or severe cases of COVID-19 in participants treated with AZD1222  Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary
0 Comments
Nov 24 2020 Allerød, Denmark –Pharmaceutical companies worldwide are diligently working overtime to produce an accepted COVID-19 vaccine. While this work continues, other companies are already planning how to distribute a potential vaccine.  Perhaps the most significant challenge exists in temperature control, as some COVID-19 vaccine candidates will require ultra-low temperature (ULT), typically ranging from
0 Comments
KENILWORTH, N.J.–(BUSINESS WIRE) November 16, 2020 — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced a collaboration with the Bill & Melinda Gates Foundation (the foundation) where the foundation is committing to provide funding to support a pivotal Phase 3 study investigating a once-monthly oral pre-exposure prophylaxis (PrEP)1
0 Comments
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 16, 2020– Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met
0 Comments
Nov 20 2020 Life science, research and industrial laboratories undertaking temperature control applications can now minimize the environmental footprint of their operations with a new range of digitally-controlled bath circulators designed to enable significant water and energy savings, while using low global warming potential (GWP) hydrocarbon refrigerants. Offering superior performance, ease of use, and flexible,
0 Comments
Wednesday, November 18, 2020 Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose;170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group Efficacy was consistent across age, gender, race and ethnicity demographics; observed efficacy in adults
0 Comments
Reviewed by Emily Henderson, B.Sc.Nov 18 2020 Using a remotely-delivered, algorithm-driven program for disease management, patients experienced significant improvement in cholesterol and blood pressure levels, according to late-breaking research presented today at the American Heart Association’s Scientific Sessions 2020. The virtual meeting is Friday, November 13-Tuesday, November 17, 2020, and is a premier global exchange
0 Comments
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 11, 2020– Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has completed case accrual for the first interim analysis of the Phase 3 COVE study of mRNA-1273, its COVID-19 vaccine candidate. Moderna has seen
0 Comments
Nov 13 2020 Porvair Sciences reports, due to promising results, it has agreed with its collaborative partners to make additional investment in the CEAT project** which aims to dramatically improve the diagnosis and treatment of ovarian cancer. In the initial stage of the CEAT (Cluster for Epigenomic and Antibody Drug Conjugate Therapeutics) project – Porvair
0 Comments
12 November 2020 — The CALAVI Phase II trials for Calquence (acalabrutinib) in patients hospitalised with respiratory symptoms of COVID-19 did not meet the primary efficacy endpoint. The addition of Calquence to best supportive care (BSC) did not increase the proportion of patients who remained alive and free of respiratory failure. No new safety signal for Calquence was observed in the
0 Comments
Nov 12 2020 A new center at the University of Cambridge, in collaboration with AstraZeneca and GSK, aims to use AI to make medical discoveries, accelerate the development of precision medicine and develop new treatments On 11 November the University of Cambridge announced a five-year agreement with AstraZeneca and GSK to fund the Cambridge Centre
0 Comments
Daix (France), November 10, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced conclusions from its end-of-phase II meeting with the U.S. Food and Drug
0 Comments
Using a set of different monoclonal antibodies, researchers determined different mutations in the SARS-CoV-2 spike protein that leads to resistance. Understanding these resistant mutations is important in developing effective therapeutic strategies. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the COVID-19 pandemic, infects host cells via the spike proteins on the virus surface.
0 Comments
PRINCETON, N.J.–(BUSINESS WIRE) November 3, 2020 — Bristol Myers Squibb (NYSE:BMY) today announced positive results from POETYK PSO-1, the first pivotal Phase 3 trial evaluating deucravacitinib (BMS-986165), a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of patients with moderate to severe plaque psoriasis. POETYK PSO-1 evaluated 6 mg of deucravacitinib once
0 Comments
Reviewed by Emily Henderson, B.Sc.Nov 6 2020 A new study has shown pregnant women with obesity could reduce the health risks for their infants through improved diet and more physical activity. Research published today in the journal PLosMed investigates the impact of high glucose in mothers with gestational diabetes mellitus (GDM) and changes to infants
0 Comments
OSLO, Norway and CHENGDU, China. 03 November,2020— CEPI, the Coalition for Epidemic Preparedness Innovations, today announced that it will fund the development of the protein-based  S-Trimer COVID-19 vaccine candidate by Sichuan Clover Biopharmaceuticals, Inc (China) (“Clover”) through a global pivotal Phase 2/3 efficacy clinical trial and to licensure in China and globally, if the vaccine is
0 Comments
Nov 6 2020 Eurofins, the global leader in the field of analytical services and a pioneer in food authenticity testing since its creation, is pleased to announce the launch of the TOFoo (True Organic Food) project. The aim of this collaborative project, comprised of five partners from the food industry, laboratory analysis, and digital sectors,
0 Comments
GAITHERSBURG, Md., Nov. 04, 2020 (GLOBE NEWSWIRE) – Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the signing of a non-binding Heads of Terms document with the Australian Government to supply 40 million doses of the Company’s COVID-19 vaccine candidate, NVX-CoV2373, for the Australian community. “This arrangement with the
0 Comments
Nov 4 2020 REGENHU, a leading global bioprinting company, today announced the launch of the R-GEN platform and SHAPER, a new bioprinter and software designed to cover the entire biofabrication process. Bioprinting has experienced unpreceded growth in the past decade. This technique has evolved rapidly from developing printing biomaterials to tissues and more complex structures
0 Comments
NEW YORK–(BUSINESS WIRE) October 27, 2020 — Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for filing and granted Priority Review designation to the company’s New Drug Application (NDA) for abrocitinib (100mg and 200mg), an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate
0 Comments
INDIANAPOLIS, Oct. 28, 2020 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) announced today an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab (LY-CoV555) 700 mg, an investigational neutralizing antibody, for $375 million. The U.S. government will accept the vials of bamlanivimab if it is granted an Emergency Use Authorization (EUA) by the U.S. Food
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 30 2020 The same biochemical triggers that spur a “fight or flight” response when we encounter threats may help tumor cells to thrive. A team of researchers from Roswell Park Comprehensive Cancer Center is looking at ways to disrupt that dynamic so that cancer treatments can be more effective. Their
0 Comments
SARASOTA, Fla. and NOVATO, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) — GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of intrathecally administered GTX-102, an investigational treatment for Angelman syndrome, today announced positive interim data from the Phase 1/2 study of GTX-102. Preliminary results from the first five patients treated
0 Comments